Alzheimer’s has long been considered irreversible, but new research challenges that assumption. Scientists discovered that severe drops in the brain’s energy supply help drive the disease—and ...

Time-limited venetoclax–obinutuzumab was the predominant first-line regimen, while continuous BTK inhibitor therapy remained nearly as common, and chemoimmunotherapy was rarely selected. Enrichment ...

Forbes contributors publish independent expert analyses and insights. John Sviokla covers GenAI/AI's impact on commerce and society. This voice experience is generated by AI. Learn more. This voice ...

Acalabrutinib in combination with venetoclax reduced the risk of disease progression or death by 35% compared with investigator’s choice of chemotherapy. The Food and Drug Administration (FDA) has ...

Looking for work but struggling to land a job interview? Money might help. Some job seekers are paying recruiters to help get a foot in the door, a practice known as "reverse recruitment" in which ...

With a reverse mortgage, homeowners aged 62 or older can tap a valuable asset for cash without making monthly payments. Instead, payment is due when you sell the house, stop living in the house ...

Ricursive Intelligence, founded by two former Google researchers and valued at $4 billion, is among several efforts to automate the creation of artificial intelligence. Anna Goldie and Azalia ...

Recursion Pharmaceuticals' AI-based approach has the potential to transform the pharmaceutical industry. However, it is still chasing clinical wins that would demonstrate the power of its strategy.

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...